---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-112193"
form_type: "8-K"
ticker: "HCTI"
cik: "0001839285"
company_name: "Healthcare Triangle, Inc."
filed_at: "2026-10-23T21:20:37+00:00"
generated_at: "2026-10-23T21:22:03.480793+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Healthcare Triangle holders approve reverse split up to 1:25, plus 20% share-issuance authority

## Summary
- Proposal 1 passed 20,163,583 for vs 93,410 against, authorizing one or more reverse splits at ratios from 1:2 to 1:25, exact ratio to be set by the Board.
- Aggregate split ratio capped at 1:25; the filing gives no specific ratio or effective date for the reverse split.
- Proposal 2 approved 20,123,343 to 132,881, allowing 20% Issuances below the Minimum Price for purposes of Nasdaq Listing Rule 5635(d).
- Proposal 3 approved 20,105,936 to 150,521, amending the 2020 Stock Incentive Plan to remove reverse-stock-split adjustments.
- 20,257,026 shares (53.69% of 37,730,008 outstanding) were represented at the Oct. 23, 2026 virtual special meeting; the adjournment proposal also passed.

## SEC filing metadata
- accession: 0001213900-26-112193
- form_type: 8-K
- ticker: HCTI
- cik: 0001839285
- company_name: Healthcare Triangle, Inc.
- filed_at: 2026-10-23T21:20:37+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1839285/000121390026112193/0001213900-26-112193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1839285/000121390026112193/ea0309560-8k_healthcare.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-112193
- JSON: https://secwatch.observer/filing/0001213900-26-112193.json
- Plain text: https://secwatch.observer/filing/0001213900-26-112193.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.